Zydus receives approvals from the USFDA for Lansoprazole Tablets and Linagliptin tablets

Ahmedabad, 29 November, 2018

Zydus Cadila has received the final approval from the USFDA to market Lansoprazole delayed release orally disintegrating tablets (US RLD- Prevacid), 15 mg and 30 mg and tentative approval for Linagliptin tablets (US RLD- Tradjenta), 5 mg.

Lansoprazole is in a class of drugs called proton pump inhibitors (PPI) which blocks the production of acid by the stomach. Proton pump inhibitors are used for the treatment of conditions such as ulcers, gastroesophageal reflux disease (GERD) and Zollinger-Ellison syndrome that are caused by stomach acid. Lansoprazole, like other proton-pump inhibitors, blocks the enzyme in the wall of the stomach that produces acid. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The group now has 236 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

***